losartan has been researched along with Hypertension, Pulmonary in 30 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Hypertension, Pulmonary: Increased VASCULAR RESISTANCE in the PULMONARY CIRCULATION, usually secondary to HEART DISEASES or LUNG DISEASES.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Forty patients with COPD and pulmonary hypertension (Tran tricuspid pressure gradient (TTPG) = 30 mmHg) were randomised to losartan 50 mg or placebo." | 9.11 | Pilot study of losartan for pulmonary hypertension in chronic obstructive pulmonary disease. ( Beddoes, RJ; Higham, MA; Morrell, NW; Phillips, PG; Robinson, PJ; Shakur, BH, 2005) |
| "Alterations in lung angiotensin converting enzyme (ACE) activity in monocrotaline (MCT)-induced pulmonary hypertension in rats have suggested a pathophysiologic role for angiotensin II (AII) in pulmonary vascular remodeling." | 7.69 | Lung angiotensin receptor binding characteristics during the development of monocrotaline-induced pulmonary hypertension. ( Baughn, J; Cassis, L; Fettinger, M; Gillespie, M; Lipke, D; Shenoy, U, 1997) |
| " To determine if increases in AII contribute to the development of pulmonary hypertension in MCT-treated rats, we examined the effect of chronic administration of the nonpeptide AII receptor antagonist Losartan on indices of pulmonary hypertension, Losartan (DuP 753; 10 mg/kg s." | 7.68 | Angiotensin II and monocrotaline-induced pulmonary hypertension: effect of losartan (DuP 753), a nonpeptide angiotensin type 1 receptor antagonist. ( Cassis, LA; Fitz, R; Gillespie, MN; Painter, DJ; Rippetoe, PE; Soltis, EE, 1992) |
| "APE-induced pulmonary hypertension is aggravated by active pulmonary vasoconstriction." | 5.38 | Losartan exerts no protective effects against acute pulmonary embolism-induced hemodynamic changes. ( Dias, CA; Montenegro, MF; Neto-Neves, EM; Tanus-Santos, JE, 2012) |
| "Pretreatment with losartan decreased shunt-induced pulmonary vascular resistance and medial thickness by 51% and 35%, respectively." | 5.33 | Prevention of pulmonary vascular remodeling and of decreased BMPR-2 expression by losartan therapy in shunt-induced pulmonary hypertension. ( Brimioulle, S; Fesler, P; Hubloue, I; Huez, S; Kerbaul, F; Naeije, R; Remmelink, M; Rondelet, B; Salmon, I; Van Beneden, R, 2005) |
| "Losartan is a potent, nonpeptide, angiotensin II type 1 receptor antagonist." | 5.29 | Prevention of thromboxane A2 receptor-mediated pulmonary hypertension by a nonpeptide angiotensin II type 1 receptor antagonist. ( Bertolino, F; Bessac, AM; John, GW; Jover, B; Maffre, M; Valentin, JP, 1994) |
| "To evaluate efficacy of losartan, a blocker of angiotensin receptors, in combined treatment of secondary pulmonary hypertension (SPH) in patients with chronic obstructive bronchitis (COB)." | 5.11 | [Blockers of angiotensin receptors: a novel approach to the treatment of secondary pulmonary hypertension]. ( Butorov, IV; Butorov, SI; Verbitskiĭ, ON, 2004) |
| " Forty patients with COPD and pulmonary hypertension (Tran tricuspid pressure gradient (TTPG) = 30 mmHg) were randomised to losartan 50 mg or placebo." | 5.11 | Pilot study of losartan for pulmonary hypertension in chronic obstructive pulmonary disease. ( Beddoes, RJ; Higham, MA; Morrell, NW; Phillips, PG; Robinson, PJ; Shakur, BH, 2005) |
| "Losartan treatment improved PVS-associated pulmonary hypertension and intimal hyperplasia and might be a beneficial prophylactic therapy for patients at high risk of developing PVS after pulmonary vein surgery." | 3.80 | Losartan ameliorates "upstream" pulmonary vein vasculopathy in a piglet model of pulmonary vein stenosis. ( Caldarone, CA; Coles, JG; Fu, YY; Ide, H; Kato, H; Maynes, JT; Teichert, AM; Weisel, RD; Zhu, J, 2014) |
| "to study the clinical and hemodynamic effects and safety of the ACE inhibitor dirotone and AT1-receptor antagonist losartan in secondary pulmonary hypertension (PH) in patients with chronic obstructive bronchitis (COB)." | 3.73 | [A new approach to treating secondary pulmonary hypertension]. ( Butorov, IV; Butorov, SI; Verbitskiĭ, ON, 2005) |
| "Losartan could reduce pulmonary arterial collagen I expression, it may be one of the therapeutic mechanisms on hypoxic pulmonary hypertension of losartan." | 3.72 | [The effects of losartan on pulmonary arterial collagen and AT1 in chronic hypoxic rats]. ( Chen, XJ; Cheng, DY; Guan, J; Su, QL; Wang, H; Zhang, Y, 2004) |
| "The aim of this study was to investigate the effect of prophylactic treatment with the angiotensin type 1 (AT1) receptor antagonist losartan on right ventricular hypertrophy and cardiac angiotensin 1-converting enzyme (ACE) activity in a rat model of monocrotaline-induced pulmonary hypertension." | 3.69 | Effect of losartan on right ventricular hypertrophy and cardiac angiotensin I-converting enzyme activity in pulmonary hypertensive rats. ( Fernandez-Alfonso, MS; Ganten, D; Kreutz, R; Paul, M, 1996) |
| "Alterations in lung angiotensin converting enzyme (ACE) activity in monocrotaline (MCT)-induced pulmonary hypertension in rats have suggested a pathophysiologic role for angiotensin II (AII) in pulmonary vascular remodeling." | 3.69 | Lung angiotensin receptor binding characteristics during the development of monocrotaline-induced pulmonary hypertension. ( Baughn, J; Cassis, L; Fettinger, M; Gillespie, M; Lipke, D; Shenoy, U, 1997) |
| " To determine if increases in AII contribute to the development of pulmonary hypertension in MCT-treated rats, we examined the effect of chronic administration of the nonpeptide AII receptor antagonist Losartan on indices of pulmonary hypertension, Losartan (DuP 753; 10 mg/kg s." | 3.68 | Angiotensin II and monocrotaline-induced pulmonary hypertension: effect of losartan (DuP 753), a nonpeptide angiotensin type 1 receptor antagonist. ( Cassis, LA; Fitz, R; Gillespie, MN; Painter, DJ; Rippetoe, PE; Soltis, EE, 1992) |
| "APE-induced pulmonary hypertension is aggravated by active pulmonary vasoconstriction." | 1.38 | Losartan exerts no protective effects against acute pulmonary embolism-induced hemodynamic changes. ( Dias, CA; Montenegro, MF; Neto-Neves, EM; Tanus-Santos, JE, 2012) |
| "Losartan delayed disease progression, decreased right ventricular afterload and pulmonary vascular remodeling, and restored right ventricular-arterial coupling in rats with PAH." | 1.38 | Dysregulated renin-angiotensin-aldosterone system contributes to pulmonary arterial hypertension. ( Boonstra, A; de Man, FS; Dorfmüller, P; Eddahibi, S; Fadel, E; François, C; Guignabert, C; Handoko, ML; Humbert, M; Perros, F; Postmus, PE; Rain, S; Ruiter, G; Schalij, I; Simonneau, G; Tu, L; van der Velden, J; Vonk-Noordegraaf, A, 2012) |
| "Pretreatment with losartan decreased shunt-induced pulmonary vascular resistance and medial thickness by 51% and 35%, respectively." | 1.33 | Prevention of pulmonary vascular remodeling and of decreased BMPR-2 expression by losartan therapy in shunt-induced pulmonary hypertension. ( Brimioulle, S; Fesler, P; Hubloue, I; Huez, S; Kerbaul, F; Naeije, R; Remmelink, M; Rondelet, B; Salmon, I; Van Beneden, R, 2005) |
| "Hypoxia produced right ventricular hypertrophy of about 100% after 3 wk, which reversed with normoxia recovery." | 1.31 | Modulation of angiotensin II receptor expression during development and regression of hypoxic pulmonary hypertension. ( Adamy, C; Adnot, S; Chassagne, C; Dubois-Randé, JL; Eddahibi, S; Marotte, F; Rideau, D; Samuel, JL; Teiger, E, 2000) |
| "Losartan is a potent, nonpeptide, angiotensin II type 1 receptor antagonist." | 1.29 | Prevention of thromboxane A2 receptor-mediated pulmonary hypertension by a nonpeptide angiotensin II type 1 receptor antagonist. ( Bertolino, F; Bessac, AM; John, GW; Jover, B; Maffre, M; Valentin, JP, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (23.33) | 18.2507 |
| 2000's | 11 (36.67) | 29.6817 |
| 2010's | 11 (36.67) | 24.3611 |
| 2020's | 1 (3.33) | 2.80 |
| Authors | Studies |
|---|---|
| Fried, ND | 1 |
| Morris, TM | 1 |
| Whitehead, A | 1 |
| Lazartigues, E | 1 |
| Yue, X | 1 |
| Gardner, JD | 1 |
| Friedberg, MK | 1 |
| Cho, MY | 1 |
| Li, J | 1 |
| Assad, RS | 1 |
| Sun, M | 1 |
| Rohailla, S | 1 |
| Honjo, O | 1 |
| Apitz, C | 1 |
| Redington, AN | 1 |
| Zhu, J | 1 |
| Ide, H | 1 |
| Fu, YY | 1 |
| Teichert, AM | 1 |
| Kato, H | 1 |
| Weisel, RD | 1 |
| Maynes, JT | 1 |
| Coles, JG | 1 |
| Caldarone, CA | 1 |
| Chai, PJ | 1 |
| Yuan, YM | 1 |
| Luo, L | 1 |
| Guo, Z | 1 |
| Yang, M | 1 |
| Ye, RS | 1 |
| Luo, C | 1 |
| Wang, XM | 1 |
| Zhou, TF | 2 |
| Liu, B | 1 |
| Wei, L | 1 |
| Shi, K | 1 |
| Zhao, SS | 1 |
| Hua, YM | 1 |
| Liu, HM | 2 |
| Bozbaş, SS | 1 |
| Bozbaş, H | 1 |
| Atar, A | 1 |
| Ulubay, G | 1 |
| Oner Eyüboğlu, F | 1 |
| Yilmaz, R | 1 |
| Han, SX | 1 |
| He, GM | 1 |
| Wang, T | 1 |
| Chen, L | 1 |
| Ning, YY | 1 |
| Luo, F | 1 |
| An, J | 1 |
| Yang, T | 1 |
| Dong, JJ | 1 |
| Liao, ZL | 1 |
| Xu, D | 1 |
| Wen, FQ | 1 |
| Xie, L | 1 |
| Lin, P | 1 |
| Xie, H | 1 |
| Xu, C | 1 |
| Dias, CA | 1 |
| Neto-Neves, EM | 1 |
| Montenegro, MF | 1 |
| Tanus-Santos, JE | 1 |
| de Man, FS | 1 |
| Tu, L | 1 |
| Handoko, ML | 1 |
| Rain, S | 1 |
| Ruiter, G | 1 |
| François, C | 1 |
| Schalij, I | 1 |
| Dorfmüller, P | 1 |
| Simonneau, G | 1 |
| Fadel, E | 1 |
| Perros, F | 1 |
| Boonstra, A | 1 |
| Postmus, PE | 1 |
| van der Velden, J | 1 |
| Vonk-Noordegraaf, A | 1 |
| Humbert, M | 1 |
| Eddahibi, S | 2 |
| Guignabert, C | 1 |
| Chen, S | 1 |
| Zhou, H | 1 |
| Wang, L | 1 |
| Krohn, J | 1 |
| Bjune, C | 1 |
| Butorov, IV | 2 |
| Verbitskiĭ, ON | 2 |
| Butorov, SI | 2 |
| Guan, J | 1 |
| Cheng, DY | 1 |
| Chen, XJ | 1 |
| Zhang, Y | 1 |
| Wang, H | 1 |
| Su, QL | 1 |
| Ueno, Y | 1 |
| Takagi, A | 1 |
| Kawana, M | 1 |
| Kasanuki, H | 1 |
| Rondelet, B | 1 |
| Kerbaul, F | 1 |
| Van Beneden, R | 1 |
| Hubloue, I | 1 |
| Huez, S | 1 |
| Fesler, P | 1 |
| Remmelink, M | 1 |
| Brimioulle, S | 1 |
| Salmon, I | 1 |
| Naeije, R | 1 |
| Morrell, NW | 2 |
| Higham, MA | 1 |
| Phillips, PG | 1 |
| Shakur, BH | 1 |
| Robinson, PJ | 1 |
| Beddoes, RJ | 1 |
| Yuan, LX | 1 |
| Li, M | 1 |
| Gao, J | 1 |
| Bertolino, F | 2 |
| Valentin, JP | 2 |
| Maffre, M | 2 |
| Jover, B | 2 |
| Bessac, AM | 2 |
| John, GW | 2 |
| Kreutz, R | 1 |
| Fernandez-Alfonso, MS | 1 |
| Ganten, D | 1 |
| Paul, M | 1 |
| Kiely, DG | 1 |
| Cargill, RI | 1 |
| Wheeldon, NM | 1 |
| Coutie, WJ | 1 |
| Lipworth, BJ | 1 |
| Cassis, L | 1 |
| Shenoy, U | 1 |
| Lipke, D | 1 |
| Baughn, J | 1 |
| Fettinger, M | 1 |
| Gillespie, M | 1 |
| Chassagne, C | 1 |
| Adamy, C | 1 |
| Rideau, D | 1 |
| Marotte, F | 1 |
| Dubois-Randé, JL | 1 |
| Adnot, S | 1 |
| Samuel, JL | 1 |
| Teiger, E | 1 |
| Cassis, LA | 1 |
| Rippetoe, PE | 1 |
| Soltis, EE | 1 |
| Painter, DJ | 1 |
| Fitz, R | 1 |
| Gillespie, MN | 1 |
4 trials available for losartan and Hypertension, Pulmonary
| Article | Year |
|---|---|
Comparative effects of losartan and nifedipine therapy on exercise capacity, Doppler echocardiographic parameters and endothelin levels in patients with secondary pulmonary hypertension.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Diastol | 2010 |
[Blockers of angiotensin receptors: a novel approach to the treatment of secondary pulmonary hypertension].
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Blood Gas Analysis; Blood Pressure; Blood Pressure M | 2004 |
Pilot study of losartan for pulmonary hypertension in chronic obstructive pulmonary disease.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Exercise Tole | 2005 |
Haemodynamic and endocrine effects of type 1 angiotensin II receptor blockade in patients with hypoxaemic cor pulmonale.
Topics: Aged; Aldosterone; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphen | 1997 |
26 other studies available for losartan and Hypertension, Pulmonary
| Article | Year |
|---|---|
Angiotensin II type 1 receptor mediates pulmonary hypertension and right ventricular remodeling induced by inhaled nicotine.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Arterial Pressure; Disease Models, Animal; E-Cigar | 2021 |
Adverse biventricular remodeling in isolated right ventricular hypertension is mediated by increased transforming growth factor-β1 signaling and is abrogated by angiotensin receptor blockade.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Connective Tissue Growth Factor; Endoth | 2013 |
Discussion.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Hypertension, Pulmonary; Losartan; Pulmonary Veins | 2014 |
Losartan ameliorates "upstream" pulmonary vein vasculopathy in a piglet model of pulmonary vein stenosis.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Newborn; Antigens, CD; Cadherins; Constri | 2014 |
Losartan for progressive pulmonary vein stenosis: a possible solution?
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Hypertension, Pulmonary; Losartan; Pulmonary Veins | 2014 |
Activation of renin-angiotensin-aldosterone system (RAAS) in the lung of smoking-induced pulmonary arterial hypertension (PAH) rats.
Topics: Angiotensin II; Angiotensin-Converting Enzyme 2; Animals; Blood Pressure; Blotting, Western; Heart V | 2015 |
[Changes of MMP-2,9 and TIMP-1 expressions in rats with pulmonary arterial hypertension after captopril and losartan interventions].
Topics: Animals; Captopril; Hypertension, Pulmonary; Losartan; Male; Matrix Metalloproteinase 2; Matrix Meta | 2009 |
Losartan and nifedipine therapy in patients with secondary pulmonary hypertension.
Topics: Anti-Arrhythmia Agents; Blood Pressure; Endothelium, Vascular; Humans; Hypertension, Pulmonary; Losa | 2010 |
Losartan attenuates chronic cigarette smoke exposure-induced pulmonary arterial hypertension in rats: possible involvement of angiotensin-converting enzyme-2.
Topics: Air Pollutants; Angiotensin-Converting Enzyme 2; Animals; Antihypertensive Agents; Blood Pressure; H | 2010 |
Effects of atorvastatin and losartan on monocrotaline-induced pulmonary artery remodeling in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Arterioles; Atorvastatin; Base Sequence; Calcium C | 2010 |
Losartan exerts no protective effects against acute pulmonary embolism-induced hemodynamic changes.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood Pressure; Hypertens | 2012 |
Dysregulated renin-angiotensin-aldosterone system contributes to pulmonary arterial hypertension.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Case-Control Studies; Cells, Cultured; Disease Pro | 2012 |
The effect of losartan intervention on the regulation of pulmonary arterial collagen expression by protein kinase C in chronic hypoxic rat models.
Topics: Animals; Collagen; Hypertension, Pulmonary; Losartan; Protein Kinase C; Pulmonary Artery; Rats; Rats | 2002 |
Uveal effusion and angle-closure glaucoma in primary pulmonary hypertension.
Topics: Aged; Antihypertensive Agents; Conjunctiva; Corneal Edema; Dilatation, Pathologic; Female; Glaucoma, | 2003 |
[The effects of losartan on pulmonary arterial collagen and AT1 in chronic hypoxic rats].
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Chronic Disease; Collagen; Hypertension, Pulmonary | 2004 |
Pulmonary hypertension during epileptic seizure with evidence of increased angiotensin II in pulmonary artery.
Topics: Aged; Angiotensin II; Anticonvulsants; Catheterization, Swan-Ganz; Drug Therapy, Combination; Epilep | 2005 |
Prevention of pulmonary vascular remodeling and of decreased BMPR-2 expression by losartan therapy in shunt-induced pulmonary hypertension.
Topics: Animals; Antihypertensive Agents; Arteriovenous Shunt, Surgical; Gene Expression Regulation; Hyperte | 2005 |
[Effects of Losartan on expression of heme oxygenases in volume-overloaded rats with left-to-right shunt].
Topics: Animals; Arteriovenous Shunt, Surgical; Down-Regulation; Female; Heme Oxygenase (Decyclizing); Heme | 2005 |
[A new approach to treating secondary pulmonary hypertension].
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Bronchitis, Chronic; Drug Administration Schedule; | 2005 |
[Losartan prevents pulmonary hypertension induced by a thromboxane A2 analog].
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Angiotensin II; Animals; Antihyp | 1994 |
Prevention of thromboxane A2 receptor-mediated pulmonary hypertension by a nonpeptide angiotensin II type 1 receptor antagonist.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Angiotensin II; Angiotensin Rece | 1994 |
Effect of losartan on right ventricular hypertrophy and cardiac angiotensin I-converting enzyme activity in pulmonary hypertensive rats.
Topics: Animals; Antihypertensive Agents; Biphenyl Compounds; Heart Ventricles; Hemodynamics; Humans; Hypert | 1996 |
Use of pulsed-wave Doppler echocardiography to measure changes in MPAP. Is further validation required?
Topics: Acute Disease; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhib | 1997 |
Lung angiotensin receptor binding characteristics during the development of monocrotaline-induced pulmonary hypertension.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Binding, Competitive; Biphenyl C | 1997 |
Modulation of angiotensin II receptor expression during development and regression of hypoxic pulmonary hypertension.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Animals; Antihypertensive Agents | 2000 |
Angiotensin II and monocrotaline-induced pulmonary hypertension: effect of losartan (DuP 753), a nonpeptide angiotensin type 1 receptor antagonist.
Topics: Angiotensin II; Animals; Biphenyl Compounds; Body Weight; Hypertension, Pulmonary; Imidazoles; Losar | 1992 |